Clinical trial
A Phase 1 Trial Combining WEE1 Inhibitor Adavosertib (AZD1775) With Radiation Therapy for Metastatic or Inoperable and Ineligible for Definitive Chemoradiation Esophageal and Gastroesophageal Junction Cancer
NCT04460937 is registered in ClinicalTrials.gov with National Cancer Institute (NCI) as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 1 Trial Combining WEE1 Inhibitor Adavosertib (AZD1775) With Radiation Therapy for Metastatic or Inoperable and Ineligible for Definitive Chemoradiation Esophageal and Gastroesophageal Junction Cancer
- Lead sponsor
- National Cancer Institute (NCI)
- Phase
- Phase 1
- Overall status
- Active, not recruiting
- Start date
- April 9, 2021
- Completion date
- December 18, 2026
- Enrollment
- 4 (actual)
- Sites
- 7
Conditions
As the registry lists them; a condition with its own page is linked.
clinical stage iii esophageal adenocarcinoma ajcc v8, clinical stage iii esophageal squamous cell carcinoma ajcc v8, clinical stage iii gastroesophageal junction adenocarcinoma ajcc v8, clinical stage iv esophageal adenocarcinoma ajcc v8, clinical stage iv esophageal squamous cell carcinoma ajcc v8, clinical stage iv gastroesophageal junction adenocarcinoma ajcc v8, clinical stage iva esophageal adenocarcinoma ajcc v8, clinical stage iva esophageal squamous cell carcinoma ajcc v8, clinical stage iva gastroesophageal junction adenocarcinoma ajcc v8, clinical stage ivb esophageal adenocarcinoma ajcc v8, clinical stage ivb esophageal squamous cell carcinoma ajcc v8, clinical stage ivb gastroesophageal junction adenocarcinoma ajcc v8, distal esophagus adenocarcinoma, gastric cardia adenocarcinoma, metastatic esophageal adenocarcinoma, metastatic esophageal squamous cell carcinoma, metastatic gastroesophageal junction adenocarcinoma, metastatic malignant neoplasm in the brain, metastatic malignant neoplasm in the leptomeninges, pathologic stage iii esophageal adenocarcinoma ajcc v8, pathologic stage iii esophageal squamous cell carcinoma ajcc v8, pathologic stage iii gastroesophageal junction adenocarcinoma ajcc v8, pathologic stage iiia esophageal adenocarcinoma ajcc v8, pathologic stage iiia esophageal squamous cell carcinoma ajcc v8, pathologic stage iiia gastroesophageal junction adenocarcinoma ajcc v8, pathologic stage iiib esophageal adenocarcinoma ajcc v8, pathologic stage iiib esophageal squamous cell carcinoma ajcc v8, pathologic stage iiib gastroesophageal junction adenocarcinoma ajcc v8, pathologic stage iv esophageal adenocarcinoma ajcc v8, pathologic stage iv esophageal squamous cell carcinoma ajcc v8, pathologic stage iv gastroesophageal junction adenocarcinoma ajcc v8, pathologic stage iva esophageal adenocarcinoma ajcc v8, pathologic stage iva esophageal squamous cell carcinoma ajcc v8, pathologic stage iva gastroesophageal junction adenocarcinoma ajcc v8, pathologic stage ivb esophageal adenocarcinoma ajcc v8, pathologic stage ivb esophageal squamous cell carcinoma ajcc v8, pathologic stage ivb gastroesophageal junction adenocarcinoma ajcc v8, postneoadjuvant therapy stage iii esophageal adenocarcinoma ajcc v8, postneoadjuvant therapy stage iii esophageal squamous cell carcinoma ajcc v8, postneoadjuvant therapy stage iii gastroesophageal junction adenocarcinoma ajcc v8, postneoadjuvant therapy stage iiia esophageal adenocarcinoma ajcc v8, postneoadjuvant therapy stage iiia esophageal squamous cell carcinoma ajcc v8, postneoadjuvant therapy stage iiia gastroesophageal junction adenocarcinoma ajcc v8, postneoadjuvant therapy stage iiib esophageal adenocarcinoma ajcc v8, postneoadjuvant therapy stage iiib esophageal squamous cell carcinoma ajcc v8, postneoadjuvant therapy stage iiib gastroesophageal junction adenocarcinoma ajcc v8, postneoadjuvant therapy stage iv esophageal adenocarcinoma ajcc v8, postneoadjuvant therapy stage iv esophageal squamous cell carcinoma ajcc v8, postneoadjuvant therapy stage iv gastroesophageal junction adenocarcinoma ajcc v8, postneoadjuvant therapy stage iva esophageal adenocarcinoma ajcc v8, postneoadjuvant therapy stage iva esophageal squamous cell carcinoma ajcc v8, postneoadjuvant therapy stage iva gastroesophageal junction adenocarcinoma ajcc v8, postneoadjuvant therapy stage ivb esophageal adenocarcinoma ajcc v8, postneoadjuvant therapy stage ivb esophageal squamous cell carcinoma ajcc v8, postneoadjuvant therapy stage ivb gastroesophageal junction adenocarcinoma ajcc v8, unresectable esophageal adenocarcinoma, unresectable esophageal carcinoma, unresectable esophageal squamous cell carcinoma, unresectable gastroesophageal junction adenocarcinoma